Headache News and Research

Latest Headache News and Research

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.

26 Jan 2022

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

A new preprint available on medRxiv* demonstrates the marked improvement in the immune response when the mRNA vaccine BNT162b2, from Pfizer/BioNTech, is used for the third dose after a primary two-dose series of an inactivated whole virus vaccine.

25 Jan 2022

Neurological complications of the SARS-CoV-2 vaccine

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case series presenting with neurological manifestations after the coronavirus disease 2019 (COVID-19) vaccination, followed by a literature review, to propose hypotheses on how neurological symptoms might develop after vaccination.

24 Jan 2022

Eligible adults urged to take part in world-first COVID-19 study of antivirals

Adults over the age of 50 or with an underlying health condition who test positive for COVID-19 are being urged to sign up for a world-first COVID-19 study which is providing life-saving antivirals to thousands of people.

24 Jan 2022

Short- and long-term systemic responses in the golden hamster following SARS-CoV-2 or influenza A virus infection

A group of researchers used the golden hamster as a model system to better understand the long-term impacts of SARS-CoV-2 infection.

24 Jan 2022

SARS-CoV-2 Omicron associated with fewer lower and more upper respiratory tract symptoms

Researchers assess the impact of the SARS-CoV-2 Omicron variant of concern on symptoms of SARS-CoV-2 infection.

23 Jan 2022

Study highlights the neurologic manifestations linked with COVID-19 in hospitalized children

Of hospitalized children who tested or were presumed positive for SARS-CoV-2, 44% developed neurological symptoms, and these kids were more likely to require intensive care than their peers who didn't experience such symptoms, according to a new study led by a pediatrician-scientist at UPMC and the University of Pittsburgh School of Medicine.

22 Jan 2022

Experts highlight the neurological effects of SARS-CoV-2 and the need for rigorous research

SARS-CoV-2 was initially identified as a respiratory virus, but it can affect the entire body, including the nervous system.

20 Jan 2022

Females more prone to long-term post-COVID-19 symptoms

In a recent study published in the Journal of Clinical Medicine, researchers described the results of a multi-center study (LONG-COVID-EXP-CM) that investigated sex differences in coronavirus disease 2019 (COVID-19)-related symptoms and long-term post-COVID-19 symptoms in a group of previously hospitalized COVID-19 survivors in a large Spanish population.

19 Jan 2022

"Nocebo effect" accounts for 76% of all adverse events in the COVID-19 vaccine trial group

The placebo effect is the well-known phenomenon of a person's physical or mental health improving after taking a treatment with no pharmacological therapeutic benefit – a sugar pill, or a syringe full of saline, for example.

18 Jan 2022

Study investigates whether immune responses to BNT162b2 vaccine differ in subjects with and without prior SARS-CoV-2 infection

A new paper published in the journal JCI Insight reports on the differential levels of immunity achieved in those with and without a history of prior infection with the virus following one and two doses of the earliest vaccines to be approved for emergency use.

17 Jan 2022

COVID-19 vaccination breakthrough infections in a real-world setting

Researchers describe the pattern and characteristics of infections after COVID-19 vaccination.

13 Jan 2022

Association of vaccination status with Long COVID symptoms

Scientists examined whether vaccination was associated with reporting long-term symptoms post-SARS-CoV-2 infection.

10 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

Melatonin found to inhibit SARS-CoV-2 entry into mice brains

New research recently unveiled the utility of melatonin and melatonin-derived medicines in reducing brain entry of severe acute respiratory syndrome coronavirus 2 and subsequently preventing long-term neurological consequences of coronavirus disease 2019.

6 Jan 2022

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality.

4 Jan 2022

Exercise performance in vaccinated and unvaccinated individuals previously infected with SARS-CoV-2

A cross-sectional report from Israel demonstrated the protective effect of BNT162b2 mRNA vaccine (Pfizer–BioNTech) even after mild to moderate COVID-19).

4 Jan 2022

COVID-19 vaccine appears safe in children aged 5–11 Years

A new report notes menial or nil severe adverse events from vaccination against COVID-19 in children and therefore recommends COVID-19 vaccination among children aged 5-11 years old.

31 Dec 2021

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Research suggests that a single booster dose of NVX-CoV2373 given approximately six months after the primary series induced significant increases in humoral antibodies, while also exhibiting an acceptable safety profile.

29 Dec 2021

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomized controlled trial published in The Lancet.

23 Dec 2021

Headache News and Research

Latest Headache News and Research

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Neurological complications of the SARS-CoV-2 vaccine

Eligible adults urged to take part in world-first COVID-19 study of antivirals

Short- and long-term systemic responses in the golden hamster following SARS-CoV-2 or influenza A virus infection

SARS-CoV-2 Omicron associated with fewer lower and more upper respiratory tract symptoms

Study highlights the neurologic manifestations linked with COVID-19 in hospitalized children

Experts highlight the neurological effects of SARS-CoV-2 and the need for rigorous research

Females more prone to long-term post-COVID-19 symptoms

"Nocebo effect" accounts for 76% of all adverse events in the COVID-19 vaccine trial group

Study investigates whether immune responses to BNT162b2 vaccine differ in subjects with and without prior SARS-CoV-2 infection

COVID-19 vaccination breakthrough infections in a real-world setting

Association of vaccination status with Long COVID symptoms

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

Melatonin found to inhibit SARS-CoV-2 entry into mice brains

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Exercise performance in vaccinated and unvaccinated individuals previously infected with SARS-CoV-2

COVID-19 vaccine appears safe in children aged 5–11 Years

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Headache News and Research

Latest Headache News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in